AMSilk extends Series C financing to EUR 54 million backed by renowned investors
Proceeds from the financing will be used to accelerate the ongoing scale-up of AMSilk’s industrialization and commercialization projects worldwide to meet the increasing demand for innovative materials.
© AMSilk GmbH
From production at AMSilk
IZB alumnus AMSilk GmbH, a world leader in supplying innovative high-performance bio-based silk materials, announced beginning of April that it has successfully raised an additional EUR 25 million in an extended Series C financing led by existing investor ATHOS (AT Newtec) with participation from Novo Holdings, Cargill, and MIG Capital.
AMSilk’s outstanding technology platform, based on silk proteins, produces bio-fabricated materials that can be utilized across a variety of applications such as textile fibers, medical devices and consumer goods.
Proceeds from the financing will enable AMSilk to accelerate the ongoing scale-up of its industrialization and commercialization projects worldwide, to meet the ever-increasing demand for AMSilk’s innovative materials.
AMSilk’s unique bio-fabrication reprograms microorganisms to enable them to produce silk proteins into usable forms such as powders, hydrogels, fibers, and coatings. Coupled with its unique fermentation process, this allows the Company to produce complex proteins in large quantities for various market segments including textiles, medical use or consumer goods. AMSilk’s bio-fabricated silk materials are 100% protein, fully biodegradable and do not include any source of micro plastics.
“We are delighted to have closed this successful financing round which validates our technology and underpins our ongoing development as we scale-up and expand our commercial operations.”
Ulrich Scherbel, Chief Executive Officer of AMSilk
Ulrich Scherbel, Chief Executive Officer of AMSilk, says: “We are delighted to have closed this successful financing round which validates our technology and underpins our ongoing development as we scale-up and expand our commercial operations. We will invest in technology to ensure that we continue to provide innovative, attractive solutions to our customers, and improve the commercial supply of our products to expand our business.”
Dr Wolfgang Colberg, Chairman of the Advisory Board, adds: “This fundraising is a significant step to accelerate the upscaling of AMSilk. This will now create the capabilities to produce in large volumes and meet the high demand growth from our customers, enabling them to create sustainable products in harmony with nature.”
Daniel Kolb, Investment Manager at ATHOS KG, states: “ATHOS has been investing in revolutionary technologies ever since. We are highly interested in bio-materials, because of their proven ability to change the world for the better. As one of the founding investors, we continue to support AMSilk in this important step to scale up their production. Their game-changing products can have a real impact on the market.”
Since the successful EUR 29 million financing in 2021, the Company has invested in partnership agreements with world-leading brands in the apparel, medical and automotive industry, and supply contracts with leaders from the Biotech industry.
Supplying high-performance biopolymers
AMSilk GmbH is the world’s first industrial supplier of vegan silk biopolymers. AMSilk’s high-performance biopolymers have the unique functional properties of the natural product they are based on. AMSilk offers its innovative range of high-performance Biosteel® fibers for textiles and industrial applications worldwide and has announced collaborations and partnerships with world leading brands. The organic high-performance material can be used in multiple ways and is suited for medical devices as well as for personal care products. AMSilk biopolymers give such products unique properties. Among other things, the polymers are biocompatible, safe and robust. AMSilk invites you to discover more at www.amsilk.com.